Stage III Hepatocellular Carcinoma AJCC v8 Clinical Trials
28 clinical trials for Stage III Hepatocellular Carcinoma AJCC v8 across international registries, including 12 currently recruiting participants. Compare status, phase, eligibility criteria and locations.
- Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer — RECRUITING · PHASE2
- Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial — RECRUITING · PHASE1
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax — RECRUITING · PHASE1
- Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer — RECRUITING · PHASE1
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial — RECRUITING · PHASE3
- Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer — RECRUITING · PHASE1
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
- Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study — RECRUITING · PHASE4
- AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease — RECRUITING · PHASE1
- Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer — RECRUITING · PHASE1
- Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer — RECRUITING · PHASE2
- Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma — RECRUITING · PHASE2
- A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab — TERMINATED · PHASE2
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver — ACTIVE_NOT_RECRUITING · PHASE2
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer — TERMINATED · PHASE1
- Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE2
- Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma — SUSPENDED · PHASE1
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV — ACTIVE_NOT_RECRUITING · PHASE1
- Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) — ACTIVE_NOT_RECRUITING · NA
- Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant — TERMINATED · PHASE2
- Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer — ACTIVE_NOT_RECRUITING · PHASE1
- Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma — NOT_YET_RECRUITING · PHASE2
- 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer — COMPLETED · PHASE2
- Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer — TERMINATED · PHASE2
- An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer — COMPLETED · NA
- Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer — COMPLETED · PHASE2
- Y-90 Versus SBRT for Inoperable HCC — WITHDRAWN · PHASE2
- Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma — COMPLETED · NA
Refine this search